The FDA solicited comments on these requirements in the notice of proposed rulemaking and has evaluated and responded to them in the preamble to the final rule.
( ( The ( FDA solicited ) ) ( ( ( ( ( comments ( on ( these requirements ) ) ) ( in ( ( the notice ) ( of ( proposed rulemaking ) ) ) ) ) and ) ( has ( ( ( ( ( evaluated and ) responded ) ( to them ) ) ( in ( the preamble ) ) ) ( to ( the ( final rule ) ) ) ) ) ) . ) )
(ROOT (S (NP (DT The) (NNP FDA) (NNP solicited)) (VP (VP (VBZ comments) (PP (IN on) (NP (DT these) (NNS requirements))) (PP (IN in) (NP (NP (DT the) (NN notice)) (PP (IN of) (NP (VBN proposed) (NN rulemaking)))))) (CC and) (VP (VBZ has) (VP (VBN evaluated) (CC and) (VBN responded) (PP (TO to) (NP (PRP them))) (PP (IN in) (NP (DT the) (NN preamble))) (PP (TO to) (NP (DT the) (JJ final) (NN rule)))))) (. .)))
The FDA mostly received criticisms about the proposed rules and plan to use the criticism to find the plan's current flaws.
( ( The FDA ) ( mostly ( ( ( ( ( received criticisms ) ( about ( the ( proposed rules ) ) ) ) and ) ( plan ( to ( use ( the ( criticism ( to ( find ( ( the ( plan 's ) ) ( current flaws ) ) ) ) ) ) ) ) ) ) . ) ) )
(ROOT (S (NP (DT The) (NNP FDA)) (ADVP (RB mostly)) (VP (VP (VBD received) (NP (NNS criticisms)) (PP (IN about) (NP (DT the) (VBN proposed) (NNS rules)))) (CC and) (VP (VBP plan) (S (VP (TO to) (VP (VB use) (NP (DT the) (NN criticism) (S (VP (TO to) (VP (VB find) (NP (NP (DT the) (NN plan) (POS 's)) (JJ current) (NNS flaws))))))))))) (. .)))